Adel Abdulaziz Alsuhaibani

Dr. Adel Abdulaziz Alsuhaibani

Medicine, King Saud University, Riyadh, Ar Riyāḑ, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Journal of Medical Systems
Verified
Journal Article
Closed access
PDF file
Mohamad-Hani TemsahMohamad-Hani Temsah
Mohamad-Hani Temsah
AAAbdullah N. Alhuzaimi
Abdullah N. Alhuzaimi
MAMohammed Almansour
Mohammed Almansour
FAFadi saleh Aljamaan
Fadi saleh Aljamaan
Khalid AlhasanKhalid Alhasan
Khalid Alhasan
RNRakan Nazer
Rakan Nazer

1 December 2020 in Risk Management and Healthcare Policy
Verified
Journal Article
Open access
PDF file
MAMohammed AlRukban
Mohammed AlRukban
YAYazed AlRuthia
Yazed AlRuthia
MAMajed Almasaoud
Majed Almasaoud
MAMohammad Al-Owairdhi
Mohammad Al-Owairdhi
AAAnwar Alsouan
Anwar Alsouan
AAAlan Aleidan
Alan Aleidan
Objective(s): The aim of this study was to explore community pharmacists’ views toward the antibiotics dispensing law that was enforced in May 2018 and bans the sale of antibiotics without a prescription in community pharmacy settings in Saudi Arabia. Moreover, the potential impact of the law enforcement on the sales of oral antibiotics in Saudi Arabia was also explored. Methods: A questionnaire-based cross-sectional study was conducted between September 2019 and March 2020 in Riyadh, Saudi Arabia. A multistage sampling technique was used to recruit community pharmacists from different districts. Pharmacists who consented to participate and reported practicing prior to the law enforcement were interviewed about their views of the law using a 14-item newly developed questionnaire. The annual sales of oral antibiotics for the years of 2017, 2018, and 2019 were retrieved from the Saudi Food and Drug Authority (SFDA) database. Results: Two hundred and eighty six pharmacists consented to participate and met the inclusion criteria. After the law enforcement, approximately 51% of the participants reported that the percentage of patients seeking antibiotics without a prescription is less than 25%. Moreover, the majority (87.41%) reported a drop in the sales of antibiotics. Additionally, about 90% of the participants believed that the rate of inappropriate use of antibiotics will decrease as a result of the law enforcement. About 41% of the participants reported that the law has negatively impacted their pharmacies’ profits. The sales of oral antibiotics have seen a 16.6% drop in the year of 2019 as compared to 2017. Conclusion: The antibiotics dispensing law is favorably perceived among community pharmacists in Saudi Arabia despite some concerns about its impact on their sales. Exploring different business models that delink the profits from the volume of antibiotics sales is necessary for this vital industry to thrive.

AAAseel Alsuwayegh
Aseel Alsuwayegh
IAIbrahim Almaghlouth
Ibrahim Almaghlouth
MAMajed Almasaoud
Majed Almasaoud
AAAbdullah Sulaiman Alzaid
Abdullah Sulaiman Alzaid
AAAdel Abdulaziz Alsuhaibani
Adel Abdulaziz Alsuhaibani
YAYazed AlRuthia
Yazed AlRuthia
Background: Belimumab use for the management of systemic lupus erythematosus (SLE) has been limited, in part due to its high acquisition cost relative to the standard of care (SoC) and the uncertainties about its cost-effectiveness. Therefore, the aim of this study was to compare the cost and effectiveness of belimumab versus the SoC alone for the management of SLE using real-world data from the perspective of public healthcare payers in Saudi Arabia. Methods: Data were retrieved from a national prospective cohort of SLE, Saudi Arabia. Adult SLE patients (≥18 yrs.) treated with belimumab plus the SoC or the SoC alone for at least six months were recruited. The effectiveness was measured using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). Unit costs for health services and prescription drugs were retrieved from the Saudi ministry of health. Nonparametric bootstrapping with inverse probability weighting was conducted to generate the 95% confidence limits for the cost and effectiveness. Results: A total of 15 patients on belimumab plus the SoC and 41 patients on the SoC alone met the inclusion criteria and were included in the analysis. The majority of patients were females (91.07%) with a mean age of 38 years. The mean difference in cost and SLEDAI-2K score reduction between belimumab versus the SoC were USD 5303.16 [95% CI: USD 2735.61–USD 7802.52] and 3.378 [95% CI: 1.769–6.831], respectively. Belimumab demonstrated better effectiveness but higher cost in 96% of the bootstrap cost-effectiveness distributions. Conclusion: Future studies should use more robust research designs and a larger sample size to confirm the findings of this study.

1 July 2017 in Saudi Journal of Ophthalmology
Verified
Journal Article
Open access
HAHind Manaa Alkatan
Hind Manaa Alkatan
AAAsma Al-Mohizea
Asma Al-Mohizea
AAAdel Abdulaziz Alsuhaibani
Adel Abdulaziz Alsuhaibani
Localized amyloidosis of the eyelid is uncommon and is classically associated with systemic manifestations. We present an interesting case of a localized eyelid mass misdiagnosed as a recurrent chalazion presenting in an 85-year-old Saudi gentleman with no definite associate findings suggestive of an underlying systemic amyloid disease. Debulking surgery was subsequently performed. Proper diagnosis was reached based on the histopathologic examination of the excised tissue, which demonstrated the typical Congo red staining of the amyloid deposits.